DAYVIGO (lemborexant) is an orexin receptor antagonist approved for treating adult patients with insomnia, who experience challenges with sleep onset and/or maintenance. It has received approval for insomnia treatment in over 15 countries, such as Japan, the United States, Canada, Australia, and various Asian nations.
DAYVIGO functions by inhibiting the activity of a neurotransmitter in the brain known as orexin, which is believed to be involved in signaling the brain to awaken. Inhibiting the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is believed to dampen the drive to stay awake.
Eisai Inc. presented studies on DA...
